1 Global Phage Therapy Market Outlook
The global Phage Therapy market is projected to exhibit substantial growth in the coming years, with a CAGR of 10.92% from 2025 to 2033, reaching a total market size of $241.56 million USD in 2025. Phage Therapy, also known as viral phage therapy or phagotherapy, is a therapeutic approach that utilizes bacteriophages, which are viruses that specifically target and kill bacteria. These viruses are nature’s way of controlling bacterial populations and have the unique ability to inject their genetic material into bacteria, using the host’s machinery to replicate themselves, ultimately leading to the destruction of the bacterial host. This makes phage therapy a promising alternative to traditional antibiotics, especially in the face of growing antibiotic resistance. Phage therapy has a wide range of applications, including human health, animal health, agriculture, and the food industry. In human medicine, it can be used to treat infections that are resistant to antibiotics, such as MRSA. In animal health, phages can help control diseases in livestock and poultry. In agriculture, they can stimulate crop rhizosphere immunity and control soil-borne diseases. In the food industry, phage therapy can prevent product decay and the spread of bacterial diseases, ensuring safer food production and handling environments.
Figure Global Phage Therapy Market Size and Growth Rate (2025-2033)
2 Phage Therapy Market Growth Drivers and Constraints
The growth of the Phage Therapy market is driven by several key factors. Firstly, the increasing prevalence of antibiotic-resistant infections has led to a renaissance in phage research. With the limited discovery and development of new antibiotics, phage therapy has emerged as a potential alternative for treating multidrug-resistant bacterial infections. The Centers for Disease Control and Prevention (CDC) reported that in 2019, approximately 2 million people in the United States contracted an antibiotic-resistant infection, with at least 23,000 people dying each year. The World Health Organization also noted that over 490,000 persons worldwide were infected with multidrug-resistant tuberculosis in 2016. Secondly, the growing understanding of the human microbiome and its role in health and disease has opened new avenues for phage therapy. Phages can be used to modulate the microbiome, addressing both infectious and non-infectious diseases. Lastly, the phage therapeutics market is active in investment and research, with increasing financing and cooperative transactions. For example, Adaptive Phage Therapeutics (APT) closed a $40.75 million Series B investment round in 2021, and Locus Biosciences secured up to $25 million in financing from Hercules Capital, Inc. to develop more precise engineered phage therapies.
However, there are also limiting factors that may hinder the growth of the Phage Therapy market. One of the main challenges is the presence of alternative treatments for antimicrobial-resistant infections. Many bacterial infections can still be treated with antibacterial agents and prevented by vaccinations, and an increasing number of drugs are entering the market for the treatment of antimicrobial-resistant infections. Additionally, regulatory policies and standards for phage therapy are not yet perfect. The production and application of phages lack quality control standards and safety evaluation systems, and there is no clear standard for phage isolation and purification, which makes the efficacy of isolated phage preparations variable.
3 Phage Therapy Market Innovations and M&A Activities
The Phage Therapy market is witnessing significant technological innovations and corporate activities. Technological advancements in DNA sequencing and artificial intelligence (AI) have accelerated phage screening and therapeutic construction. Companies like AmpliPhi Biosciences (APHB) have sequenced phages to quickly find and identify the required phages, while startups like APT have established PhageBank, a gene database for storing phages. The use of synthetic biology and gene editing tools has also expanded the scope of phage action, enabling more precise therapy. Engineered phages based on CRISPR, artificial synthesis, and other technologies can effectively solve problems of bacterial tolerance and phage self-toxicity.
On the corporate front, there have been notable mergers, acquisitions, and expansions. For instance, Locus Biosciences acquired EpiBiome’s high-throughput bacteriophage discovery platform in 2018 to develop products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Phagelux AgriHealth announced multiple agricultural commercial collaborations in 2020, including an exclusive European sale, marketing, and product development collaboration with DCM for its AgriPhage line of biopesticides. Proteon Pharmaceuticals secured an investment of €21 million in 2021 to accelerate the commercialization of its bacteriophage products, aiming to reduce the reliance on antibiotics in aquaculture and livestock farming. These activities indicate a vibrant and growing market, with companies actively seeking to expand their capabilities and market share through strategic partnerships and investments.
4 Global Phage Therapy Market Analysis by Type
In 2025, the global Phage Therapy market is forecasted to reach a size of 241.56 million USD. The market share distribution by type is as follows: DsDNA Bacteriophage is expected to hold the largest share with a market size of 212.55 million USD, accounting for approximately 87.99% of the total market. SsDNA Bacteriophage is projected to have a market size of 17.36 million USD, representing about 7.27% of the market. SsRNA Bacteriophage is anticipated to have a market size of 3.57 million USD, making up around 1.48% of the market. The ‘Others’ category is estimated to have a market size of 8.08 million USD, constituting approximately 3.34% of the total market share.
Table Global Phage Therapy Market Size and Share by Type in 2025
Type | Market Size in 2025 (M USD) | Market Share in 2025 (%) |
|---|---|---|
DsDNA Bacteriophage | 212.55 | 87.99% |
SsDNA Bacteriophage | 17.36 | 7.27% |
SsRNA Bacteriophage | 3.57 | 1.48% |
Others | 8.08 | 3.34% |
5 Global Phage Therapy Market Analysis by Application
In 2025, the global Phage Therapy market is forecasted to reach a size of 241.56 million USD, with the following distribution by application: Animal Health is expected to have a market size of 102.82 million USD, accounting for approximately 42.56% of the total market. Human Health is projected to have a market size of 63.47 million USD, representing about 26.28% of the market. Agriculture is anticipated to have a market size of 38.27 million USD, making up around 15.84% of the market. The Food Industry is estimated to have a market size of 27.44 million USD, constituting approximately 11.36% of the total market. The ‘Others’ category is expected to have a market size of 9.57 million USD, which is about 3.96% of the market share.
Table Global Phage Therapy Market Size and Share by Application in 2025
Application | Market Size in 2025 (M USD) | Market Share in 2025 (%) |
|---|---|---|
Animal Health | 102.82 | 42.56% |
Human Health | 63.47 | 26.28% |
Agriculture | 38.27 | 15.84% |
Food Industry | 27.44 | 11.36% |
Others | 9.57 | 3.96% |
6 Global Phage Therapy Market Analysis by Region
In 2025, the global Phage Therapy market is forecasted to reach a size of 241.56 million USD, with the following regional distribution: North America is expected to have a market size of 115.04 million USD, accounting for approximately 47.62% of the total market. Europe is projected to have a market size of 78.00 million USD, representing about 32.29% of the market. Asia Pacific is anticipated to have a market size of 36.11 million USD, making up around 14.95% of the market. South America is estimated to have a market size of 9.22 million USD, constituting approximately 3.82% of the total market. The Middle East and Africa are expected to have a market size of 3.18 million USD, which is about 1.32% of the market share.
Figure Global Phage Therapy Market Share by Region in 2025
7 Top 3 Companies of Global Phage Therapy Market
7.1 CJ Cheiljedang
Company Introduction and Business Overview:
CJ Cheiljedang, established in 1953 and headquartered in South Korea, is a multifaceted food company with a global presence. It is renowned for manufacturing a wide array of products, including food ingredients, ambient, frozen, and chilled packaged food products, pharmaceuticals, and biotechnology solutions. The company’s commitment to innovation and quality has positioned it as a leader in the phage therapy segment, focusing on leveraging biotechnology to address critical health and agricultural challenges.
Products Offered:
CJ Cheiljedang’s phage therapy products are primarily targeted at the animal health sector. Their flagship product, CJ BIO BIOTECTOR, is the world’s first bacteriophage cocktail of feed additive. It is designed to combat Salmonella, C. perfringens, and Escherichia coli, offering a strong antimicrobial activity without the risk of resistance development. This product helps decrease horizontal and vertical infection of bacterial diseases in farms and prevents Salmonella contamination in eggs and chickens, ensuring the supply of safe livestock products.
Sales Revenue in the Latest Year:
In the latest year reported, CJ Cheiljedang’s phage therapy business achieved a revenue of 25.24 million USD, reflecting a robust growth trajectory and a market share of 15.84%. This revenue figure underscores the company’s significant contribution to the global phage therapy market and its ability to capitalize on the growing demand for alternative antibacterial solutions.
7.2 NPO Microgen
Company Introduction and Business Overview:
NPO Microgen, founded in 2003 and based in Russia, is a prominent player in the field of biotechnology, specializing in the development and production of a variety of medical and biological products. The company’s portfolio includes vaccines, toxoids, blood products, bacteriophages, diagnostic preparations, growth media, and allergens. NPO Microgen’s primary sales region is Europe, where it has established a strong reputation for quality and innovation in phage therapy.
Products Offered:
NPO Microgen offers a range of phage therapy products aimed at human health applications. Notable among these are the E.coli-Proteus bacteriophage, which specifically targets and lyses bacteria such as P. vulgaris, P. mirabilis, and E. coli, and is used in the treatment and prevention of purulent inflammatory and enteric diseases. The company also produces Streptococcus bacteriophage, Complex pyobacteriophage, and Klebsiella purified polyvalent bacteriophage, each designed to address specific bacterial infections and support complex therapeutic approaches.
Sales Revenue in the Latest Year:
NPO Microgen reported a phage therapy revenue of 15.81 million USD in the latest year, accounting for a market share of 9.92%. This revenue highlights the company’s effectiveness in catering to the European market’s demand for phage-based therapeutic solutions and its continuous efforts to expand its product offerings and market reach.
7.3 Micreos
Company Introduction and Business Overview:
Micreos, established in 2005 and headquartered in the Netherlands, is a leading developer of phage technology for the targeted control of bacteria. The company’s business overview emphasizes its commitment to providing natural and effective alternatives to traditional antibiotics, particularly in the food industry and human health sectors. Micreos is known for its innovative approach to harnessing the power of phages to ensure food safety and address health challenges.
Products Offered:
Micreos offers a diverse range of products under the PhageGuard brand, which includes PhageGuard Listex for combating Listeria, PhageGuard S. for Salmonella, and PhageGuard E. for E. coli in the food industry. These products are designed to be applied during food processing to prevent cross-contamination and ensure the safety of cooked meat, poultry, fish, dairy, cheese, and produce. In the human health sector, Micreos has developed Gladskin, a series of endolysin-based products that target S. aureus, including the resistant MRSA, and are used to treat inflammatory skin conditions such as eczema, acne, rosacea, and psoriasis.
Sales Revenue in the Latest Year:
In the most recent year, Micreos achieved a phage therapy revenue of 13.39 million USD, with a market share of 8.40%. This revenue figure demonstrates Micreos’s success in commercializing its phage technology and its ability to meet the growing consumer demand for natural and effective antibacterial solutions in both the food and health sectors.